Collapse to view only § 285f-2. Research and research training regarding tuberculosis
- § 285f. Purpose of Institute
- § 285f-1. Research centers regarding chronic fatigue syndrome
- § 285f-2. Research and research training regarding tuberculosis
- § 285f-3. Sexually transmitted disease clinical research and training awards
- § 285f-4. Microbicide research and development
- § 285f-5. Research centers for pathogens of pandemic concern
§ 285f. Purpose of Institute
The general purpose of the National Institute of Allergy and Infectious Diseases is the conduct and support of research, training, health information dissemination, and other programs with respect to allergic and immunologic diseases and disorders and infectious diseases, including tropical diseases.
(July 1, 1944, ch. 373, title IV, § 446, as added Pub. L. 99–158, § 2, Nov. 20, 1985, 99 Stat. 855; amended Pub. L. 103–43, title IX, § 901, June 10, 1993, 107 Stat. 164.)
§ 285f–1. Research centers regarding chronic fatigue syndrome
(a) The Director of the Institute, after consultation with the advisory council for the Institute, may make grants to, or enter into contracts with, public or nonprofit private entities for the development and operation of centers to conduct basic and clinical research on chronic fatigue syndrome.
(b) Each center assisted under this section shall use the facilities of a single institution, or be formed from a consortium of cooperating institutions, meeting such requirements as may be prescribed by the Director of the Institute.
(July 1, 1944, ch. 373, title IV, § 447, as added Pub. L. 103–43, title IX, § 902(a), June 10, 1993, 107 Stat. 164.)
§ 285f–2. Research and research training regarding tuberculosis
In carrying out section 285f of this title, the Director of the Institute shall conduct or support research and research training regarding the cause, diagnosis, early detection, prevention and treatment of tuberculosis.
(July 1, 1944, ch. 373, title IV, § 447A, formerly § 447, as added Pub. L. 103–183, title III, § 302(a), Dec. 14, 1993, 107 Stat. 2235; renumbered § 447A, Pub. L. 105–392, title IV, § 401(b)(3), Nov. 13, 1998, 112 Stat. 3587; amended Pub. L. 109–482, title I, § 103(b)(27), Jan. 15, 2007, 120 Stat. 3688.)
§ 285f–3. Sexually transmitted disease clinical research and training awards
(a) In general
(b) Support of promising clinicians
(c) Excellence in certain fields
(July 1, 1944, ch. 373, title IV, § 447B, as added Pub. L. 106–505, title IX, § 901, Nov. 13, 2000, 114 Stat. 2349; amended Pub. L. 109–482, title I, § 103(b)(28), Jan. 15, 2007, 120 Stat. 3688.)
§ 285f–4. Microbicide research and development
The Director of the Institute, acting through the head of the Division of AIDS, shall, consistent with the peer-review process of the National Institutes of Health, carry out research on, and development of, safe and effective methods for use by women to prevent the transmission of the human immunodeficiency virus, which may include microbicides.
(July 1, 1944, ch. 373, title IV, § 447C, as added Pub. L. 110–293, title II, § 203(c), July 30, 2008, 122 Stat. 2941.)
§ 285f–5. Research centers for pathogens of pandemic concern
(a) In general
(b) Uses of funds
The Director of the Institute shall award funding through grants, contracts, or cooperative agreements to public or private entities to provide support for research centers described in subsection (a) for the purpose of—
(1) conducting basic research through preclinical development of new medical products or technologies, including platform technologies, to address pathogens of pandemic concern;
(2) identifying potential targets for therapeutic candidates, including antivirals, to treat such pathogens;
(3) identifying existing medical products with the potential to address such pathogens, including candidates that could be used in outpatient settings; and
(4) carrying out or supporting other research related to medical products to address such pathogens, as determined appropriate by the Director.
(c) Coordination
The Director of the Institute shall, as appropriate, provide for the coordination of activities among the centers described in subsection (a), including through—
(1) facilitating the exchange of information and regular communication among the centers, as appropriate; and
(2) requiring the periodic preparation and submission to the Director of reports on the activities of each center.
(d) Priority
(e) Collaboration
The Director of the Institute shall—
(1) collaborate with the heads of other appropriate Federal departments, agencies, and offices with respect to the identification of additional priority virus families and other viral pathogens with a significant potential to cause a pandemic; and
(2) collaborate with the Director of the Biomedical Advanced Research and Development Authority with respect to the research conducted by centers described in subsection (a), including, as appropriate, providing any updates on the research advancements made by such centers, identifying any advanced research and development needs for such countermeasures, consistent with section 247d–7e(a)(6) of this title, and taking into consideration existing manufacturing capacity and future capacity needs for such medical products or technologies, including platform technologies, supported by the centers described in subsection (a).
(f) Supplement, not supplant
(July 1, 1944, ch. 373, title IV, § 447D, as added Pub. L. 117–328, div. FF, title II, § 2301, Dec. 29, 2022, 136 Stat. 5756.)